Alpha Cognition Receives U.S. Patent for Traumatic Brain Injury Treatment

The new patent strengthens the company's intellectual property portfolio and supports its long-term strategy.

Apr. 2, 2026 at 2:59am

Got story updates? Submit your updates here. ›

Alpha Cognition Inc., a biopharmaceutical company developing treatments for neurodegenerative disorders, announced that the U.S. Patent and Trademark Office has issued a patent for its ALPHA-1062 compound to treat traumatic brain injury (TBI). The patent provides protection through 2045 and aligns with the company's plans to expand its pipeline beyond Alzheimer's disease.

Why it matters

Traumatic brain injury represents a significant unmet medical need, with an estimated total addressable market of $14 billion and no approved therapies. This patent positions Alpha Cognition to address this large, underserved patient population and enhances the commercial potential of its pipeline.

The details

The patent, titled 'ALPHA-1062 for treating Traumatic Brain Injury,' includes claims covering methods of treating both confirmed and suspected TBI using ALPHA-1062. This newly issued patent strengthens Alpha Cognition's intellectual property portfolio and complements existing patents supporting both ALPHA-1062 and ZUNVEYL®, the company's lead asset for Alzheimer's disease.

  • The U.S. Patent and Trademark Office issued the patent on March 31, 2026.
  • The patent provides protection through 2045.

The players

Alpha Cognition Inc.

A biopharmaceutical company developing treatments for neurodegenerative disorders, including Alzheimer's disease and traumatic brain injury.

Michael McFadden

Chief Executive Officer of Alpha Cognition.

ALPHA-1062

A compound being developed by Alpha Cognition for the treatment of traumatic brain injury.

ZUNVEYL®

Alpha Cognition's lead asset for the treatment of Alzheimer's disease.

Got photos? Submit your photos here. ›

What they’re saying

“This patent marks an important milestone in expanding our platform beyond Alzheimer's disease. It underscores the innovation behind ALPHA-1062 while reinforcing the long-term value of ZUNVEYL. Traumatic brain injury represents a significant unmet medical need, with an estimated total addressable market of $14 billion and no approved therapies. We believe this creates a compelling first-mover opportunity.”

— Michael McFadden, Chief Executive Officer of Alpha Cognition

What’s next

Alpha Cognition plans to advance ALPHA-1062 into clinical trials for the treatment of traumatic brain injury, leveraging the newly issued patent to strengthen its position in this large, underserved market.

The takeaway

This patent reinforces Alpha Cognition's commitment to expanding its pipeline beyond Alzheimer's disease and positions the company to address the significant unmet need in traumatic brain injury, a market with no approved therapies and an estimated $14 billion in potential value.